Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer

Journal of the Chinese Medical Association

Volumn 71, Issue 7, 2008, Pages 336-341

  Chang, P Mu Hsin ^a,b   Teng, Hao Wei ^a,b   Chen, Po Min ^a,b   Chang, Shyue Yih ^a   Chu, Pen Yuan ^a   Tsai, Tung Lung ^a   Tai, Shyh Kuan ^a   Wang, Yi Fen ^a   Huang, Jui Lin ^a   Yang, Muh Hwa ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cisplatin; Fluorouracil; Head and neck cancer; Methotrexate; Mucositis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CARCINOMA; INFECTION; LARYNX CARCINOMA; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; MALE; MOUTH CARCINOMA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; RECURRENT CANCER; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 50049130759     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(08)70135-7     Document Type: Article

References (25)

1. Hardisson D. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2003;260:502-8.
2. Chen CL, Chi CW, Liu TY. Hydroxyl radical formation and oxidative DNA damage induced by areca quid in vivo. J Toxicol Environ Health A 2002;65:327-36.
3. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 1995; 24:450-3.
4. Lin SC, Wang CP, Chen YM, Lu SY, Fann MJ, Liu CJ, Kao SY, et al. Regulation of IGFBP-5 expression during tumorigenesis and differentiation of oral keratinocytes. J Pathol 2002;198: 317-25.
5. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5:521-6.
6. Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M, Veevers A, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985;15:283-9.
7. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2644-52.
8. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;9:625-30.
9. Chi KH, Chan WK, Shu CH, Law CK, Chen SY, Yen SH, Chen KY. Elimination of dose-limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer 1995;76:2186-92.
10. Delaunoit T, Marechal R, Hendlisz A, Eisendrath P, Legendre H, Pector JC, Becker D, et al. Treatment of advanced digestive non-colon cancer with a weekly 24-hour infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination. Anticancer Drugs 2004; 15:725-8.
11. Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, et al. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. Anticancer Res 2002;22:3621-7.
12. Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, Chen YC, et al. Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers: effective and low-toxicity regimen for patients with poor general condition. Oncology 1997;54:275-80.
13. Stickel F, Jüngert B, Brueckl V, Schirner I, Brueckl WM, Männlein G, Hegewald J, et al. Weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anticancer Drugs 2003;14:745-9.
14. Yeh KH, Cheng AL, Lin MT, Hong RL, Hsu CH, Lin JF, Chang KJ, et al. A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers. Anticancer Res 1997;17:3867-71.
15. Bertino JR, Mini E, Fernandes DJ. Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. Semin Oncol 1983;10:2-5.
16. Caponigro F, Comella P, Marcolin P, Spena FR, Biglietto M, Carteni G, Lucia LD, et al. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck. Cancer 1999;85:952-9.
17. Ringborg U, Ewert G, Kinnman J, Lundqvist PG, Strander H. Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck. Cancer 1983;52:971-3.
18. Stabuc B, Markovic A, Plesnicar A, Cizej TE. Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer. Neoplasma 2000;47:248-52.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
20. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10:1245-51.
21. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:3562-7.
22. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63.
23. Schrijvers D, Johnson J, Jiminez U, Gore M, Kosmidis P, Szpirglas H, Robbins K, et al. Phase III trial of modulation of cisplatin/ fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. J Clin Oncol 1998;16:1054-9.
24. Cheng AL, Yeh KH, Lin JT, Hsu C, Liu MY. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL): a very effective regimen with good patient compliance for advanced gastric cancer. Anticancer Res 1998;18: 1267-72.
25. Bagrij T, Kralovanszky J, Gyergyay F, Kiss E, Peters GJ. Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil. Anticancer Res 1993;13:789-93.